1
|
Singh AK, Lewis CD, Boas CAWV, Diebolder P, Jethva PN, Rhee A, Song JH, Goo YA, Li S, Nickels ML, Liu Y, Rogers BE, Kapoor V, Hallahan DE. Development of a [89Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library. Clin Cancer Res 2024; 30:1293-1306. [PMID: 38277241 PMCID: PMC10984770 DOI: 10.1158/1078-0432.ccr-23-3647] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2023] [Revised: 01/23/2024] [Accepted: 01/24/2024] [Indexed: 01/28/2024]
Abstract
PURPOSE Tax-interacting protein 1 (TIP1) is a cancer-specific radiation-inducible cell surface antigen that plays a role in cancer progression and resistance to therapy. This study aimed to develop a novel anti-TIP1 human antibody for noninvasive PET imaging in patients with cancer. EXPERIMENTAL DESIGN A phage-displayed single-chain variable fragment (scFv) library was created from healthy donors' blood. High-affinity anti-TIP1 scFvs were selected from the library and engineered to human IgG1. Purified Abs were characterized by size exclusion chromatography high-performance liquid chromatography (SEC-HPLC), native mass spectrometry (native MS), ELISA, BIAcore, and flow cytometry. The labeling of positron emitter [89Zr]Zr to the lead Ab, L111, was optimized using deferoxamine (DFO) chelator. The stability of [89Zr]Zr-DFO-L111 was assessed in human serum. Small animal PET studies were performed in lung cancer tumor models (A549 and H460). RESULTS We obtained 95% pure L111 by SEC-HPLC. Native MS confirmed the intact mass and glycosylation pattern of L111. Conjugation of three molar equivalents of DFO led to the optimal DFO-to-L111 ratio of 1.05. Radiochemical purity of 99.9% and specific activity of 0.37 MBq/μg was obtained for [89Zr]Zr-DFO-L111. [89Zr]Zr-DFO-L111 was stable in human serum over 7 days. The immunoreactive fraction in cell surface binding studies was 96%. In PET, preinjection with 4 mg/kg cold L111 before [89Zr]Zr-DFO-L111 (7.4 MBq; 20 μg) significantly (P < 0.01) enhanced the tumor-to-muscle standard uptake values (SUVmax) ratios on day 5 compared with day 2 postinjection. CONCLUSIONS L111 Ab targets lung cancer cells in vitro and in vivo. [89Zr]Zr-DFO-L111 is a human antibody that will be evaluated in the first in-human study of safety and PET imaging.
Collapse
Affiliation(s)
- Abhay K Singh
- Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri
| | - Calvin D Lewis
- Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri
| | - Cristian A W V Boas
- Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri
| | - Philipp Diebolder
- Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri
| | - Prashant N Jethva
- Department of Chemistry, Washington University in St. Louis, St. Louis, Missouri
| | - Aaron Rhee
- Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri
| | - Jong Hee Song
- Mass Spectrometry Technology Access Center at the McDonnell Genome Institute (MTAC@MGI), Washington University in St. Louis, St. Louis, Missouri
| | - Young Ah Goo
- Mass Spectrometry Technology Access Center at the McDonnell Genome Institute (MTAC@MGI), Washington University in St. Louis, St. Louis, Missouri
| | - Shunqian Li
- Department of Medicine, Washington University in St. Louis, St. Louis, Missouri
| | - Michael L Nickels
- Mallinckrodt Institute of Radiology, Washington University in St. Louis, St. Louis, Missouri
- Cyclotron Facility, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri
| | - Yongjian Liu
- Mallinckrodt Institute of Radiology, Washington University in St. Louis, St. Louis, Missouri
| | - Buck E Rogers
- Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri
- Siteman Cancer Center, St. Louis, Missouri
| | - Vaishali Kapoor
- Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri
- Siteman Cancer Center, St. Louis, Missouri
| | - Dennis E Hallahan
- Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri
- Siteman Cancer Center, St. Louis, Missouri
| |
Collapse
|
2
|
McKay NS, Gordon BA, Hornbeck RC, Dincer A, Flores S, Keefe SJ, Joseph-Mathurin N, Jack CR, Koeppe R, Millar PR, Ances BM, Chen CD, Daniels A, Hobbs DA, Jackson K, Koudelis D, Massoumzadeh P, McCullough A, Nickels ML, Rahmani F, Swisher L, Wang Q, Allegri RF, Berman SB, Brickman AM, Brooks WS, Cash DM, Chhatwal JP, Day GS, Farlow MR, la Fougère C, Fox NC, Fulham M, Ghetti B, Graff-Radford N, Ikeuchi T, Klunk W, Lee JH, Levin J, Martins R, Masters CL, McConathy J, Mori H, Noble JM, Reischl G, Rowe C, Salloway S, Sanchez-Valle R, Schofield PR, Shimada H, Shoji M, Su Y, Suzuki K, Vöglein J, Yakushev I, Cruchaga C, Hassenstab J, Karch C, McDade E, Perrin RJ, Xiong C, Morris JC, Bateman RJ, Benzinger TLS. Positron emission tomography and magnetic resonance imaging methods and datasets within the Dominantly Inherited Alzheimer Network (DIAN). Nat Neurosci 2023; 26:1449-1460. [PMID: 37429916 PMCID: PMC10400428 DOI: 10.1038/s41593-023-01359-8] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2022] [Accepted: 05/15/2023] [Indexed: 07/12/2023]
Abstract
The Dominantly Inherited Alzheimer Network (DIAN) is an international collaboration studying autosomal dominant Alzheimer disease (ADAD). ADAD arises from mutations occurring in three genes. Offspring from ADAD families have a 50% chance of inheriting their familial mutation, so non-carrier siblings can be recruited for comparisons in case-control studies. The age of onset in ADAD is highly predictable within families, allowing researchers to estimate an individual's point in the disease trajectory. These characteristics allow candidate AD biomarker measurements to be reliably mapped during the preclinical phase. Although ADAD represents a small proportion of AD cases, understanding neuroimaging-based changes that occur during the preclinical period may provide insight into early disease stages of 'sporadic' AD also. Additionally, this study provides rich data for research in healthy aging through inclusion of the non-carrier controls. Here we introduce the neuroimaging dataset collected and describe how this resource can be used by a range of researchers.
Collapse
Affiliation(s)
| | | | | | - Aylin Dincer
- Washington University in St. Louis, St. Louis, MO, USA
| | - Shaney Flores
- Washington University in St. Louis, St. Louis, MO, USA
| | - Sarah J Keefe
- Washington University in St. Louis, St. Louis, MO, USA
| | | | | | | | | | - Beau M Ances
- Washington University in St. Louis, St. Louis, MO, USA
| | | | | | - Diana A Hobbs
- Washington University in St. Louis, St. Louis, MO, USA
| | | | | | | | | | | | | | - Laura Swisher
- Washington University in St. Louis, St. Louis, MO, USA
| | - Qing Wang
- Washington University in St. Louis, St. Louis, MO, USA
| | | | | | - Adam M Brickman
- Columbia University Irving Medical Center, New York, NY, USA
| | - William S Brooks
- Neuroscience Research Australia, Sydney, New South Wales, Australia
| | - David M Cash
- UK Dementia Research Institute at University College London, London, UK
- University College London, London, UK
| | - Jasmeer P Chhatwal
- Massachusetts General and Brigham & Women's Hospitals, Harvard Medical School, Boston, MA, USA
| | | | | | - Christian la Fougère
- Department of Radiology, University of Tübingen, Tübingen, Germany
- German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany
| | - Nick C Fox
- UK Dementia Research Institute at University College London, London, UK
- University College London, London, UK
| | - Michael Fulham
- Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
| | | | | | | | | | | | - Johannes Levin
- German Center for Neurodegenerative Diseases (DZNE), Munich, Germany
| | - Ralph Martins
- Edith Cowan University, Joondalup, Western Australia, Australia
| | | | | | | | - James M Noble
- Columbia University Irving Medical Center, New York, NY, USA
| | - Gerald Reischl
- Department of Radiology, University of Tübingen, Tübingen, Germany
| | | | | | - Raquel Sanchez-Valle
- Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain
| | - Peter R Schofield
- Neuroscience Research Australia, Sydney, New South Wales, Australia
- School of Biomedical Sciences, University of New South Wales, Sydney, New South Wales, Australia
| | | | | | - Yi Su
- Banner Alzheimer's Institute, Phoenix, AZ, USA
| | | | - Jonathan Vöglein
- German Center for Neurodegenerative Diseases (DZNE), Munich, Germany
- Department of Neurology, Ludwig-Maximilians-Universität München, München, Germany
| | - Igor Yakushev
- School of Medicine, Technical University of Munich, Munich, Germany
| | | | | | - Celeste Karch
- Washington University in St. Louis, St. Louis, MO, USA
| | - Eric McDade
- Washington University in St. Louis, St. Louis, MO, USA
| | | | | | - John C Morris
- Washington University in St. Louis, St. Louis, MO, USA
| | | | | |
Collapse
|
3
|
Flores S, Chen CD, Su Y, Dincer A, Keefe SJ, McKay NS, Paulick AM, Perez-Carrillo GG, Wang L, Hornbeck RC, Goyal M, Vlassenko A, Schwarz S, Nickels ML, Wong DF, Tu Z, McConathy JE, Morris JC, Benzinger TLS, Gordon BA. Investigating Tau and Amyloid Tracer Skull Binding in Studies of Alzheimer Disease. J Nucl Med 2023; 64:287-293. [PMID: 35953305 PMCID: PMC9902848 DOI: 10.2967/jnumed.122.263948] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2022] [Revised: 08/11/2022] [Accepted: 08/11/2022] [Indexed: 02/04/2023] Open
Abstract
Off-target binding of [18F]flortaucipir (FTP) can complicate quantitative PET analyses. An underdiscussed off-target region is the skull. Here, we characterize how often FTP skull binding occurs, its influence on estimates of Alzheimer disease pathology, its potential drivers, and whether skull uptake is a stable feature across time and tracers. Methods: In 313 cognitively normal and mildly impaired participants, CT scans were used to define a skull mask. This mask was used to quantify FTP skull uptake. Skull uptake of the amyloid-β PET tracers [18F]florbetapir and [11C]Pittsburgh compound B (n = 152) was also assessed. Gaussian mixture modeling defined abnormal levels of skull binding for each tracer. We examined the relationship of continuous bone uptake to known off-target binding in the basal ganglia and choroid plexus as well as skull density measured from the CT. Finally, we examined the confounding effect of skull binding on pathologic quantification. Results: We found that 50 of 313 (∼16%) FTP scans had high levels of skull signal. Most were female (n = 41, 82%), and in women, lower skull density was related to higher FTP skull signal. Visual reads by a neuroradiologist revealed a significant relationship with hyperostosis; however, only 21% of women with high skull binding were diagnosed with hyperostosis. FTP skull signal did not substantially correlate with other known off-target regions. Skull uptake was consistent over longitudinal FTP scans and across tracers. In amyloid-β-negative, but not -positive, individuals, FTP skull binding impacted quantitative estimates in temporal regions. Conclusion: FTP skull binding is a stable, participant-specific phenomenon and is unrelated to known off-target regions. Effects were found primarily in women and were partially related to lower bone density. The presence of [11C]Pittsburgh compound B skull binding suggests that defluorination does not fully explain FTP skull signal. As signal in skull bone can impact quantitative analyses and differs across sex, it should be explicitly addressed in studies of aging and Alzheimer disease.
Collapse
Affiliation(s)
- Shaney Flores
- Department of Radiology, Washington University School of Medicine, St. Louis, Missouri
| | - Charles D Chen
- Department of Radiology, Washington University School of Medicine, St. Louis, Missouri
| | - Yi Su
- Banner Alzheimer's Institute, Phoenix, Arizona
| | - Aylin Dincer
- Department of Radiology, Washington University School of Medicine, St. Louis, Missouri
| | - Sarah J Keefe
- Department of Radiology, Washington University School of Medicine, St. Louis, Missouri
| | - Nicole S McKay
- Department of Radiology, Washington University School of Medicine, St. Louis, Missouri
| | - Angela M Paulick
- Department of Radiology, Washington University School of Medicine, St. Louis, Missouri
| | | | - Liang Wang
- Department of Radiology, Washington University School of Medicine, St. Louis, Missouri
| | - Russ C Hornbeck
- Department of Radiology, Washington University School of Medicine, St. Louis, Missouri
| | - Manu Goyal
- Department of Radiology, Washington University School of Medicine, St. Louis, Missouri
- Department of Neurology, Washington University School of Medicine, St. Louis, Missouri
- Charles F. and Joanne Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, Missouri; and
| | - Andrei Vlassenko
- Department of Radiology, Washington University School of Medicine, St. Louis, Missouri
- Department of Neurology, Washington University School of Medicine, St. Louis, Missouri
| | - Sally Schwarz
- Department of Radiology, Washington University School of Medicine, St. Louis, Missouri
| | - Michael L Nickels
- Department of Radiology, Washington University School of Medicine, St. Louis, Missouri
| | - Dean F Wong
- Department of Radiology, Washington University School of Medicine, St. Louis, Missouri
| | - Zhude Tu
- Department of Radiology, Washington University School of Medicine, St. Louis, Missouri
| | | | - John C Morris
- Department of Neurology, Washington University School of Medicine, St. Louis, Missouri
- Charles F. and Joanne Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, Missouri; and
| | - Tammie L S Benzinger
- Department of Radiology, Washington University School of Medicine, St. Louis, Missouri
- Charles F. and Joanne Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, Missouri; and
| | - Brian A Gordon
- Department of Radiology, Washington University School of Medicine, St. Louis, Missouri;
- Charles F. and Joanne Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, Missouri; and
| |
Collapse
|
4
|
Flores S, Chen CD, Su Y, Dincer A, Keefe SJ, Perez‐Carrillo GG, Hornbeck RC, Goyal MS, Vlassenko AG, Schwarz S, Nickels ML, Wong DF, Tu Z, McConathy J, Morris JC, Benzinger TL, Gordon BA. Characteristics and quantitative impact of off‐target skull binding in tau PET studies of Alzheimer disease. Alzheimers Dement 2022. [DOI: 10.1002/alz.063405] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Affiliation(s)
- Shaney Flores
- Washington University in St. Louis School of Medicine St. Louis MO USA
| | - Charles D. Chen
- Washington University in St. Louis School of Medicine St. Louis MO USA
| | - Yi Su
- Banner Alzheimer's Institute Phoenix AZ USA
| | - Aylin Dincer
- Washington University in St. Louis School of Medicine St. Louis MO USA
| | - Sarah J. Keefe
- Washington University in St. Louis School of Medicine St. Louis MO USA
| | | | - Russ C. Hornbeck
- Washington University in St. Louis School of Medicine St. Louis MO USA
| | - Manu S. Goyal
- Washington University in St. Louis School of Medicine St. Louis MO USA
| | | | - Sally Schwarz
- Washington University in St. Louis School of Medicine St. Louis MO USA
| | | | - Dean F Wong
- Washington University in St. Louis School of Medicine St. Louis MO USA
| | - Zhude Tu
- Washington University in St. Louis School of Medicine St. Louis MO USA
| | | | - John C. Morris
- Washington University in St. Louis School of Medicine St. Louis MO USA
- Knight Alzheimer Disease Research Center St. Louis MO USA
| | - Tammie L.S. Benzinger
- Washington University in St. Louis School of Medicine St. Louis MO USA
- Knight Alzheimer Disease Research Center St. Louis MO USA
| | - Brian A. Gordon
- Washington University in St. Louis School of Medicine St. Louis MO USA
- Knight Alzheimer Disease Research Center St. Louis MO USA
| |
Collapse
|
5
|
Abou DS, Zerkel P, Robben J, McLaughlin M, Hazlehurst T, Morse D, Wadas TJ, Pandya DN, Oyama R, Gaehle G, Nickels ML, Thorek DL. Radiopharmaceutical Quality Control Considerations for Accelerator-Produced Actinium Therapies. Cancer Biother Radiopharm 2022; 37:355-363. [PMID: 35695807 PMCID: PMC9242709 DOI: 10.1089/cbr.2022.0010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023] Open
Abstract
Background: Alpha-particle-emitting radiotherapies are of great interest for the treatment of disseminated cancer. Actinium-225 (225Ac) produces four α-particles through its decay and is among the most attractive radionuclides for use in targeted radiotherapy applications. However, supply issues for this isotope have limited availability and increased cost for research and translation. Efforts have focused on accelerator-based methods that produce 225Ac in addition to long-lived 227Ac. Objective: The authors investigated the impact of 225Ac/227Ac material in the radiolabeling and radiopharmaceutical quality control evaluation of a DOTA chelate-conjugated peptide under good manufacturing practices. The authors use an automated module under identical conditions with either generator or accelerator-produced actinium radiolabeling. Methods: The authors have performed characterization of the radiolabeled products, including thin-layer chromatography, high-pressure liquid chromatography, gamma counting, and high-energy resolution gamma spectroscopy. Results: Peptide was radiolabeled and assessed at >95% radiochemical purity with high yields for generator produced 225Ac. The radiolabeling results produced material with subtle but detectable differences when using 225Ac/227Ac. Gamma spectroscopy was able to identify peptide initially labeled with 227Th, and at 100 d for quantification of 225Ac-bearing peptide. Conclusion: Peptides produced using 225Ac/227Ac material may be suitable for translation, but raise new issues that include processing times, logistics, and contaminant detection.
Collapse
Affiliation(s)
- Diane S. Abou
- Cyclotron Facility, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri, USA.,Department of Radiology and Washington University School of Medicine, St. Louis, Missouri, USA.,Program in Quantitative Molecular Therapeutics, Washington University School of Medicine, St. Louis, Missouri, USA
| | - Patrick Zerkel
- Cyclotron Facility, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri, USA
| | - James Robben
- Cyclotron Facility, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri, USA
| | | | | | - David Morse
- Modulation Therapeutics, Morgantown, West Virginia, USA.,Department of Cancer Physiology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USA.,Department of Physics and Oncologic Sciences, University of South Florida, Tampa, Florida, USA
| | | | - Darpan N. Pandya
- Department of Radiology, University of Iowa, Iowa City, Iowa, USA
| | - Reiko Oyama
- Cyclotron Facility, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri, USA
| | - Gregory Gaehle
- Cyclotron Facility, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri, USA
| | - Michael L. Nickels
- Cyclotron Facility, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri, USA.,Department of Radiology and Washington University School of Medicine, St. Louis, Missouri, USA
| | - Daniel L.J. Thorek
- Department of Radiology and Washington University School of Medicine, St. Louis, Missouri, USA.,Program in Quantitative Molecular Therapeutics, Washington University School of Medicine, St. Louis, Missouri, USA.,Department of Biomedical Engineering, Washington University, St. Louis, Missouri, USA.,Oncologic Imaging Program, Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri, USA.,Address correspondence to: Daniel L.J. Thorek; Department of Radiology, Washington University School of Medicine; 510 S. Kingshighway Boulevard, St. Louis, MO 63110-1010, USA
| |
Collapse
|
6
|
Buck JR, Saleh S, Claus T, Lovly C, Hight MR, Nickels ML, Noor Tantawy M, Charles Manning H. N-[ 18F]-Fluoroacetylcrizotinib: A potentially potent and selective PET tracer for molecular imaging of non-small cell lung cancer. Bioorg Med Chem Lett 2020; 30:127257. [PMID: 32631505 PMCID: PMC7357882 DOI: 10.1016/j.bmcl.2020.127257] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2020] [Revised: 05/08/2020] [Accepted: 05/09/2020] [Indexed: 12/24/2022]
Abstract
N-[18F]fluoroacetylcrizotinib, a fluorine-18 labeled derivative of the first FDA approved tyrosine kinase inhibitor (TKI) for the treatment of Anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC), crizotinib, was successfully synthesized for use in positron emission tomography (PET). Sequential in vitro biological evaluation of fluoracetylcrizotinib and in vivo biodistribution studies of [18F]fluoroacetylcrizotinib demonstrated that the biological activity of the parent compound remained unchanged, with potent ALK kinase inhibition and effective tumor growth inhibition. These results show that [18F]fluoroacetylcrizotinib has the potential to be a promising PET ligand for use in NSCLC imaging. The utility of PET in this context provides a non-invasive, quantifiable method to inform on the pharmacokinetics of an ALK-inhibitor such as crizotinib prior to a clinical trial, as well as during a trial in the event of acquired drug resistance.
Collapse
Affiliation(s)
- Jason R Buck
- Vanderbilt Center for Molecular Probes, United States; Vanderbilt University, Institute of Imaging Science, United States; Vanderbilt University Medical Center, United States
| | - Samir Saleh
- Vanderbilt Center for Molecular Probes, United States; Vanderbilt University, Institute of Imaging Science, United States; Vanderbilt University Medical Center, United States
| | - Trey Claus
- Vanderbilt Center for Molecular Probes, United States; Vanderbilt University, Institute of Imaging Science, United States; Vanderbilt University Medical Center, United States
| | - Christine Lovly
- Vanderbilt University Medical Center, United States; Vanderbilt Ingram Cancer Center, United States; Department of Hematology and Oncology, Vanderbilt University Medical Center, United States
| | - Matthew R Hight
- Vanderbilt Center for Molecular Probes, United States; Vanderbilt University, Institute of Imaging Science, United States; Vanderbilt University Medical Center, United States
| | - Michael L Nickels
- Vanderbilt Center for Molecular Probes, United States; Vanderbilt University, Institute of Imaging Science, United States; Vanderbilt University Medical Center, United States; Mallinckrodt Institute of Radiology, Washington University School of Medicine, United States
| | - M Noor Tantawy
- Vanderbilt University, Institute of Imaging Science, United States; Vanderbilt University Medical Center, United States
| | - H Charles Manning
- Vanderbilt Center for Molecular Probes, United States; Vanderbilt University, Institute of Imaging Science, United States; Vanderbilt University Medical Center, United States; Department of Radiology, Vanderbilt University Medical Center, United States.
| |
Collapse
|
7
|
Zhang X, Liu F, Payne AC, Nickels ML, Bellan LM, Manning HC. High-Yielding Radiosynthesis of [68Ga]Ga-PSMA-11 Using a Low-Cost Microfluidic Device. Mol Imaging Biol 2020; 22:1370-1379. [DOI: 10.1007/s11307-020-01515-7] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
8
|
|
9
|
Tang D, Li J, Nickels ML, Huang G, Cohen AS, Manning HC. Preclinical Evaluation of a Novel TSPO PET Ligand 2-(7-Butyl-2-(4-(2-[ 18F]Fluoroethoxy)phenyl)-5-Methylpyrazolo[1,5-a]Pyrimidin-3-yl)-N,N-Diethylacetamide ( 18F-VUIIS1018A) to Image Glioma. Mol Imaging Biol 2019; 21:113-121. [PMID: 29869061 DOI: 10.1007/s11307-018-1198-7] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
PURPOSE There is an urgent need for the development of novel positron emission tomography (PET) tracers for glioma imaging. In this study, we developed a novel PET probe ([18F]VUIIS1018A) by targeting translocator protein (TSPO), an imaging biomarker for glioma. The purpose of this preclinical study was to evaluate this novel TSPO probe for glioma imaging. PROCEDURES In this study, we synthesized [19F]VUIIS1018A and the precursor for radiosynthesis of [18F]VUIIS1018A. TSPO binding affinity was confirmed using a radioligand competitive binding assay in C6 glioma cell lysate. Further, dynamic imaging studies were performed in rats using a microPET system. These studies include displacement and blocking studies for ligand reversibility and specificity evaluation, and compartment modeling of PET data for pharmacokinetic parameter measurement using metabolite-corrected arterial input functions and PMOD. RESULTS Compared to previously reported TSPO tracers including [18F]VUIIS1008 and [18F]DPA-714, the novel tracer [18F]VUIIS1018A demonstrated higher binding affinity and BPND. Pretreatment with the cold analog [19F]VUIIS1018A could partially block tumor accumulation of this novel tracer. Further, compartment modeling of this novel tracer also exhibited a greater tumor-to-background ratio, a higher tumor binding potential and a lower brain binding potential when compared with other TSPO probes, such as [18F]DPA-714 and [18F]VUIIS1008. CONCLUSIONS These studies illustrate that [18F]VUIIS1018A can serve as a promising TSPO PET tracer for glioma imaging and potentially imaging of other solid tumors.
Collapse
Affiliation(s)
- Dewei Tang
- Center for Molecular Imaging, Shanghai University of Medicine & Health Sciences, Shanghai, China.,Department of Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, 160 Pujian Road, Pudong New District, Shanghai, 200127, China
| | - Jun Li
- Vanderbilt University Institute of Imaging Science, Vanderbilt University Medical Center, Nashville, TN, USA.,Vanderbilt Center for Molecular Probes (CMP), Vanderbilt University Medical School, 1161 21st Ave. S., AA 1105 MCN, Nashville, TN, 37232-2310, USA.,Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, TN, USA
| | - Michael L Nickels
- Vanderbilt University Institute of Imaging Science, Vanderbilt University Medical Center, Nashville, TN, USA.,Vanderbilt Center for Molecular Probes (CMP), Vanderbilt University Medical School, 1161 21st Ave. S., AA 1105 MCN, Nashville, TN, 37232-2310, USA.,Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, TN, USA
| | - Gang Huang
- Center for Molecular Imaging, Shanghai University of Medicine & Health Sciences, Shanghai, China.,Department of Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, 160 Pujian Road, Pudong New District, Shanghai, 200127, China
| | - Allison S Cohen
- Vanderbilt University Institute of Imaging Science, Vanderbilt University Medical Center, Nashville, TN, USA.,Vanderbilt Center for Molecular Probes (CMP), Vanderbilt University Medical School, 1161 21st Ave. S., AA 1105 MCN, Nashville, TN, 37232-2310, USA
| | - H Charles Manning
- Vanderbilt University Institute of Imaging Science, Vanderbilt University Medical Center, Nashville, TN, USA. .,Vanderbilt Center for Molecular Probes (CMP), Vanderbilt University Medical School, 1161 21st Ave. S., AA 1105 MCN, Nashville, TN, 37232-2310, USA. .,Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, TN, USA. .,Program in Chemical and Physical Biology, Vanderbilt University Medical Center, Nashville, TN, USA. .,Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA. .,Department of Biomedical Engineering, Vanderbilt University, Nashville, TN, USA. .,Department of Neurosurgery, Vanderbilt University Medical Center, Nashville, TN, USA.
| |
Collapse
|
10
|
Uddin MJ, Wilson AJ, Crews BC, Malerba P, Uddin MI, Kingsley PJ, Ghebreselasie K, Daniel CK, Nickels ML, Tantawy MN, Jashim E, Manning HC, Khabele D, Marnett LJ. Discovery of Furanone-Based Radiopharmaceuticals for Diagnostic Targeting of COX-1 in Ovarian Cancer. ACS Omega 2019; 4:9251-9261. [PMID: 31172046 PMCID: PMC6545551 DOI: 10.1021/acsomega.9b01093] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/16/2019] [Accepted: 05/09/2019] [Indexed: 05/03/2023]
Abstract
In vivo targeting and visualization of cyclooxygenase-1 (COX-1) using multimodal positron emission tomography/computed tomography imaging represents a unique opportunity for early detection and/or therapeutic evaluation of ovarian cancer because overexpression of COX-1 has been characterized as a pathologic hallmark of the initiation and progression of this disease. The furanone core is a common building block of many synthetic and natural products that exhibit a wide range of biological activities. We hypothesize that furanone-based COX-1 inhibitors can be designed as imaging agents for the early detection, delineation of tumor margin, and evaluation of treatment response of ovarian cancer. We report the discovery of 3-(4-fluorophenyl)-5,5-dimethyl-4-(p-tolyl)furan-2(5H)-one (FDF), a furanone-based novel COX-1-selective inhibitor that exhibits adequate in vivo stability, plasma half-life, and pharmacokinetic properties for use as an imaging agent. We describe a novel synthetic scheme in which a Lewis acid-catalyzed nucleophilic aromatic deiodo[18F]fluorination reaction is utilized for the radiosynthesis of [18F]FDF. [18F]FDF binds efficiently to COX-1 in vivo and enables sensitive detection of ovarian cancer in subcutaneous and peritoneal xenograft models in mice. These results provide the proof of principle for COX-1-targeted imaging of ovarian cancer and identify [18F]FDF as a promising lead compound for further preclinical and clinical development.
Collapse
Affiliation(s)
- Md. Jashim Uddin
- A. B.
Hancock, Jr., Memorial Laboratory for Cancer Research, Department
of Biochemistry, Chemistry and Pharmacology, Vanderbilt Institute
of Chemical Biology, Vanderbilt-Ingram Cancer Center,
and Department of Radiology
and Radiological Sciences, Vanderbilt Institute of Imaging Sciences, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States
- E-mail: . Phone: 615-484-8674. Fax: 615.343-0704 (M.J.U.)
| | - Andrew J. Wilson
- Department of Obstetrics & Gynecology, Women’s
Reproductive
Health Research Center, and Department of Ophthalmology and Visual Sciences,
Vanderbilt Eye Institute, Vanderbilt University
Medical Center, Nashville, Tennessee 37232, United States
| | - Brenda C. Crews
- A. B.
Hancock, Jr., Memorial Laboratory for Cancer Research, Department
of Biochemistry, Chemistry and Pharmacology, Vanderbilt Institute
of Chemical Biology, Vanderbilt-Ingram Cancer Center,
and Department of Radiology
and Radiological Sciences, Vanderbilt Institute of Imaging Sciences, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States
| | - Paola Malerba
- A. B.
Hancock, Jr., Memorial Laboratory for Cancer Research, Department
of Biochemistry, Chemistry and Pharmacology, Vanderbilt Institute
of Chemical Biology, Vanderbilt-Ingram Cancer Center,
and Department of Radiology
and Radiological Sciences, Vanderbilt Institute of Imaging Sciences, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States
- Department
of Pharmacy & Pharmaceutical Sciences, University of Bari “A. Moro”, Via Orabona 4, 70125 Bari, Italy
| | - Md. Imam Uddin
- Department of Obstetrics & Gynecology, Women’s
Reproductive
Health Research Center, and Department of Ophthalmology and Visual Sciences,
Vanderbilt Eye Institute, Vanderbilt University
Medical Center, Nashville, Tennessee 37232, United States
| | - Philip J. Kingsley
- A. B.
Hancock, Jr., Memorial Laboratory for Cancer Research, Department
of Biochemistry, Chemistry and Pharmacology, Vanderbilt Institute
of Chemical Biology, Vanderbilt-Ingram Cancer Center,
and Department of Radiology
and Radiological Sciences, Vanderbilt Institute of Imaging Sciences, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States
| | - Kebreab Ghebreselasie
- A. B.
Hancock, Jr., Memorial Laboratory for Cancer Research, Department
of Biochemistry, Chemistry and Pharmacology, Vanderbilt Institute
of Chemical Biology, Vanderbilt-Ingram Cancer Center,
and Department of Radiology
and Radiological Sciences, Vanderbilt Institute of Imaging Sciences, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States
| | - Cristina K. Daniel
- A. B.
Hancock, Jr., Memorial Laboratory for Cancer Research, Department
of Biochemistry, Chemistry and Pharmacology, Vanderbilt Institute
of Chemical Biology, Vanderbilt-Ingram Cancer Center,
and Department of Radiology
and Radiological Sciences, Vanderbilt Institute of Imaging Sciences, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States
| | - Michael L. Nickels
- A. B.
Hancock, Jr., Memorial Laboratory for Cancer Research, Department
of Biochemistry, Chemistry and Pharmacology, Vanderbilt Institute
of Chemical Biology, Vanderbilt-Ingram Cancer Center,
and Department of Radiology
and Radiological Sciences, Vanderbilt Institute of Imaging Sciences, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States
| | - Mohammed N. Tantawy
- A. B.
Hancock, Jr., Memorial Laboratory for Cancer Research, Department
of Biochemistry, Chemistry and Pharmacology, Vanderbilt Institute
of Chemical Biology, Vanderbilt-Ingram Cancer Center,
and Department of Radiology
and Radiological Sciences, Vanderbilt Institute of Imaging Sciences, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States
| | - Elma Jashim
- A. B.
Hancock, Jr., Memorial Laboratory for Cancer Research, Department
of Biochemistry, Chemistry and Pharmacology, Vanderbilt Institute
of Chemical Biology, Vanderbilt-Ingram Cancer Center,
and Department of Radiology
and Radiological Sciences, Vanderbilt Institute of Imaging Sciences, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States
- Martin Luther
King Jr. Academic Magnet School of Health Sciences and Engineering, 613 17th Avenue North, Nashville, Tennessee 37203, United States
| | - H. Charles Manning
- A. B.
Hancock, Jr., Memorial Laboratory for Cancer Research, Department
of Biochemistry, Chemistry and Pharmacology, Vanderbilt Institute
of Chemical Biology, Vanderbilt-Ingram Cancer Center,
and Department of Radiology
and Radiological Sciences, Vanderbilt Institute of Imaging Sciences, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States
| | - Dineo Khabele
- Department of Obstetrics & Gynecology, Women’s
Reproductive
Health Research Center, and Department of Ophthalmology and Visual Sciences,
Vanderbilt Eye Institute, Vanderbilt University
Medical Center, Nashville, Tennessee 37232, United States
- Department
of Obstetrics and Gynecology, University
of Kansas School of Medicine, Kansas
City, Kansas 66160, United States
| | - Lawrence J. Marnett
- A. B.
Hancock, Jr., Memorial Laboratory for Cancer Research, Department
of Biochemistry, Chemistry and Pharmacology, Vanderbilt Institute
of Chemical Biology, Vanderbilt-Ingram Cancer Center,
and Department of Radiology
and Radiological Sciences, Vanderbilt Institute of Imaging Sciences, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States
- E-mail: (L.J.M.)
| |
Collapse
|
11
|
Smith CT, San Juan MD, Dang LC, Katz DT, Perkins SF, Burgess LL, Cowan RL, Manning HC, Nickels ML, Claassen DO, Samanez-Larkin GR, Zald DH. Ventral striatal dopamine transporter availability is associated with lower trait motor impulsivity in healthy adults. Transl Psychiatry 2018; 8:269. [PMID: 30531858 PMCID: PMC6286354 DOI: 10.1038/s41398-018-0328-y] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/16/2018] [Revised: 11/13/2018] [Accepted: 11/15/2018] [Indexed: 12/18/2022] Open
Abstract
Impulsivity is a transdiagnostic feature of a range of externalizing psychiatric disorders. Preclinical work links reduced ventral striatal dopamine transporter (DAT) availability with heightened impulsivity and novelty seeking. However, there is a lack of human data investigating the relationship between DAT availability, particularly in subregions of the striatum, and the personality traits of impulsivity and novelty seeking. Here we collected PET measures of DAT availability (BPND) using the tracer 18F-FE-PE2I in 47 healthy adult subjects and examined relations between BPND in striatum, including its subregions: caudate, putamen, and ventral striatum (VS), and trait impulsivity (Barratt Impulsiveness Scale: BIS-11) and novelty seeking (Tridimensional Personality Questionnaire: TPQ-NS), controlling for age and sex. DAT BPND in each striatal subregion showed nominal negative associations with total BIS-11 but not TPQ-NS. At the subscale level, VS DAT BPND was significantly associated with BIS-11 motor impulsivity (e.g., taking actions without thinking) after correction for multiple comparisons. VS DAT BPND explained 13.2% of the variance in motor impulsivity. Our data demonstrate that DAT availability in VS is negatively related to impulsivity and suggest a particular influence of DAT regulation of dopamine signaling in VS on acting without deliberation (BIS motor impulsivity). While needing replication, these data converge with models of ventral striatal functions that emphasize its role as a key interface linking motivation to action.
Collapse
Affiliation(s)
- Christopher T. Smith
- 0000 0001 2264 7217grid.152326.1Department of Psychology, PMB 407817, Vanderbilt University, 2301 Vanderbilt Place, Nashville, TN 37240-7817 USA
| | - M. Danica San Juan
- 0000 0001 2264 7217grid.152326.1Department of Psychology, PMB 407817, Vanderbilt University, 2301 Vanderbilt Place, Nashville, TN 37240-7817 USA
| | - Linh C. Dang
- 0000 0001 2264 7217grid.152326.1Department of Psychology, PMB 407817, Vanderbilt University, 2301 Vanderbilt Place, Nashville, TN 37240-7817 USA
| | - Daniel T. Katz
- 0000 0001 2264 7217grid.152326.1Department of Psychology, PMB 407817, Vanderbilt University, 2301 Vanderbilt Place, Nashville, TN 37240-7817 USA
| | - Scott F. Perkins
- 0000 0001 2264 7217grid.152326.1Department of Psychology, PMB 407817, Vanderbilt University, 2301 Vanderbilt Place, Nashville, TN 37240-7817 USA
| | - Leah L. Burgess
- 0000 0001 2264 7217grid.152326.1Department of Psychology, PMB 407817, Vanderbilt University, 2301 Vanderbilt Place, Nashville, TN 37240-7817 USA
| | - Ronald L. Cowan
- 0000 0001 2264 7217grid.152326.1Department of Psychology, PMB 407817, Vanderbilt University, 2301 Vanderbilt Place, Nashville, TN 37240-7817 USA ,0000 0004 1936 9916grid.412807.8Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center, 1601 23rd Avenue South, Suite 3057, Nashville, TN 37212 USA ,0000 0004 1936 9916grid.412807.8Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Medical Center North, 1161 21st Avenue South, Nashville, TN 37232 USA
| | - H. Charles Manning
- 0000 0004 1936 9916grid.412807.8Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Medical Center North, 1161 21st Avenue South, Nashville, TN 37232 USA ,0000 0001 2264 7217grid.152326.1Department of Chemistry, Vanderbilt University, 7330 Stevenson Center, Station B 351822, Nashville, TN 37235 USA ,0000 0001 2264 7217grid.152326.1Department of Biomedical Engineering, PMB 351826, Vanderbilt University, 2301 Vanderbilt Place, Nashville, TN 37235-1826 USA ,0000 0004 1936 9916grid.412807.8Department of Neurological Surgery, Vanderbilt University Medical Center, 1161 21st Avenue South, T4224 Medical Center North, Nashville, TN 37232-2380 USA
| | - Michael L. Nickels
- 0000 0004 1936 9916grid.412807.8Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Medical Center North, 1161 21st Avenue South, Nashville, TN 37232 USA
| | - Daniel O. Claassen
- 0000 0004 1936 9916grid.412807.8Department of Neurology, Vanderbilt University Medical Center, 1161 21st Avenue South, A-0118, Nashville, TN 37232-2551 USA
| | - Gregory R. Samanez-Larkin
- 0000 0004 1936 7961grid.26009.3dDepartment of Psychology and Neuroscience, Duke University, 417 Chapel Drive, Durham, NC 27708 USA
| | - David H. Zald
- 0000 0001 2264 7217grid.152326.1Department of Psychology, PMB 407817, Vanderbilt University, 2301 Vanderbilt Place, Nashville, TN 37240-7817 USA ,0000 0004 1936 9916grid.412807.8Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center, 1601 23rd Avenue South, Suite 3057, Nashville, TN 37212 USA
| |
Collapse
|
12
|
Rosenberg AJ, Nickels ML, Schulte ML, Manning HC. Automated radiosynthesis of 5-[ 11C]l-glutamine, an important tracer for glutamine utilization. Nucl Med Biol 2018; 67:10-14. [PMID: 30359787 DOI: 10.1016/j.nucmedbio.2018.09.002] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2018] [Revised: 09/24/2018] [Accepted: 09/29/2018] [Indexed: 12/16/2022]
Abstract
INTRODUCTION The natural amino acid l-Glutamine (Gln) is essential for both cell growth and proliferation. In addition to glucose, cancer cells utilize Gln as a carbon source for ATP production, biosynthesis, and as a defense against reactive oxygen species. The utilization of [11C]Gln has been previously reported as a biomarker for tissues with an elevated demand for Gln, however, the previous reports for the preparation of [11C]Gln were found to be lacking several crucial aspects necessary for transition to human production. Namely, the presence of unreacted precursor and the use of non-commercialized, custom built, reaction platforms. Herein, we report the development and utilization of methodology for the automated production of [11C]Gln that meets institutional criteria for human use. METHODS The preparation of [11C]Gln was carried out on the GE FX2N platform. Briefly, after trapping of [11C]HCN with a solution of CsHCO3 in DMF, the [11C]CsCN was reacted with a commercially available precursor. This intermediate was then purified by HPLC and deprotected/hydrolyzed under acidic conditions. Following pH adjustment, the product was filtered to give the desired [11C]Gln as a sterile injectable. The resulting product was then analyzed for quality assurance. RESULTS Automated production by this method reliably provides over 3.7 GBq (100 mCi) of [11C]Gln. The resulting final drug product was found to have a >99% radiochemical purity, <5% of D-Gln present, no detectable impurities, and the total preparation time was roughly 45 min from the end-of-bombardment. CONCLUSIONS A fast, reliable and efficient automated radiosynthesis was developed using a commercially available module. Purifications used throughout allow for both a radiochemically and chemically pure final product solution of [11C]Gln.
Collapse
Affiliation(s)
- Adam J Rosenberg
- Vanderbilt Center for Molecular Probes, Vanderbilt University Medical Center, Nashville, TN, USA; Vanderbilt University Institute for Imaging Science, Vanderbilt University Medical Center, Nashville, TN, USA
| | - Michael L Nickels
- Vanderbilt Center for Molecular Probes, Vanderbilt University Medical Center, Nashville, TN, USA; Vanderbilt University Institute for Imaging Science, Vanderbilt University Medical Center, Nashville, TN, USA; Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, TN, USA
| | - Michael L Schulte
- Vanderbilt Center for Molecular Probes, Vanderbilt University Medical Center, Nashville, TN, USA; Vanderbilt University Institute for Imaging Science, Vanderbilt University Medical Center, Nashville, TN, USA; Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, TN, USA
| | - H Charles Manning
- Vanderbilt Center for Molecular Probes, Vanderbilt University Medical Center, Nashville, TN, USA; Vanderbilt University Institute for Imaging Science, Vanderbilt University Medical Center, Nashville, TN, USA; Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, TN, USA; Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA; Department of Biomedical Engineering, Vanderbilt University, Nashville, TN, USA; Department of Neurosurgery, Vanderbilt University Medical Center, Nashville, TN, USA; Department of Chemistry, Vanderbilt University, Nashville, TN, USA.
| |
Collapse
|
13
|
Zhang X, Liu F, Knapp KA, Nickels ML, Manning HC, Bellan LM. A simple microfluidic platform for rapid and efficient production of the radiotracer [ 18F]fallypride. Lab Chip 2018; 18:1369-1377. [PMID: 29658049 DOI: 10.1039/c8lc00167g] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
Herein, we report the development of a simple, high-throughput and efficient microfluidic system for synthesizing radioactive [18F]fallypride, a PET imaging radiotracer widely used in medical research. The microfluidic chip contains all essential modules required for the synthesis and purification of radioactive fallypride. The radiochemical yield of the tracer is sufficient for multiple animal injections for preclinical imaging studies. To produce the on-chip concentration and purification columns, we employ a simple "trapping" mechanism by inserting rows of square pillars with predefined gaps near the outlet of microchannel. Microspheres with appropriate functionality are suspended in solution and loaded into the microchannels to form columns for radioactivity concentration and product purification. Instead of relying on complicated flow control elements (e.g., micromechanical valves requiring complex external pneumatic actuation), external valves are utilized to control transfer of the reagents between different modules. The on-chip ion exchange column can efficiently capture [18F]fluoride with negligible loss (∼98% trapping efficiency), and subsequently release a burst of concentrated [18F]fluoride to the reaction cavity. A thin layer of PDMS with a small hole in the center facilitates rapid and reliable water evaporation (with the aid of azeotropic distillation and nitrogen flow) while reducing fluoride loss. During the solvent exchange and fluorination reaction, the entire chip is uniformly heated to the desired temperature using a hot plate. All aspects of the [18F]fallypride synthesis were monitored by high-performance liquid chromatography (HPLC) analysis, resulting in labelling efficiency in fluorination reaction ranging from 67-87% (n = 5). Moreover, after isolating unreacted [18F]fluoride, remaining fallypride precursor, and various by-products via an on-chip purification column, the eluted [18F]fallypride is radiochemically pure and of a sufficient quantity to allow for PET imaging (∼5 mCi). Finally, a positron emission tomography (PET) image of a rat brain injected with ∼300 μCi [18F]fallypride produced by our microfluidic chip is provided, demonstrating the utility of the product produced by the microfluidic reactor. With a short synthesis time (∼60 min) and a highly integrated on-chip modular configuration that allows for concentration, reaction, and product purification, our microfluidic chip offers numerous exciting advantages with the potential for applications in radiochemical research and clinical production. Moreover, due to its simplicity and potential for automation, we anticipate it may be easily integrated into a clinical environment.
Collapse
Affiliation(s)
- Xin Zhang
- Department of Mechanical Engineering, Vanderbilt University, Nashville, TN 37235, USA
| | | | | | | | | | | |
Collapse
|
14
|
Tang D, Li J, Buck JR, Tantawy MN, Xia Y, Harp JM, Nickels ML, Meiler J, Manning HC. Evaluation of TSPO PET Ligands [ 18F]VUIIS1009A and [ 18F]VUIIS1009B: Tracers for Cancer Imaging. Mol Imaging Biol 2018; 19:578-588. [PMID: 27853987 DOI: 10.1007/s11307-016-1027-9] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
PURPOSE Positron emission tomography (PET) ligands targeting translocator protein (TSPO) are potential imaging diagnostics of cancer. In this study, we report two novel, high-affinity TSPO PET ligands that are 5,7 regioisomers, [18F]VUIIS1009A ([18F]3A) and [18F]VUIIS1009B ([18F]3B), and their initial in vitro and in vivo evaluation in healthy mice and glioma-bearing rats. PROCEDURES VUIIS1009A/B was synthesized and confirmed by X-ray crystallography. Interactions between TSPO binding pocket and novel ligands were evaluated and compared with contemporary TSPO ligands using 2D 1H-15N heteronuclear single quantum coherence (HSQC) spectroscopy. In vivo biodistribution of [18F]VUIIS1009A and [18F]VUIIS1009B was carried out in healthy mice with and without radioligand displacement. Dynamic PET imaging data were acquired simultaneously with [18F]VUIIS1009A/B injections in glioma-bearing rats, with binding reversibility and specificity evaluated by radioligand displacement. In vivo radiometabolite analysis was performed using radio-TLC, and quantitative analysis of PET data was performed using metabolite-corrected arterial input functions. Imaging was validated with histology and immunohistochemistry. RESULTS Both VUIIS1009A (3A) and VUIIS1009B (3B) were found to exhibit exceptional binding affinity to TSPO, with observed IC50 values against PK11195 approximately 500-fold lower than DPA-714. However, HSQC NMR suggested that VUIIS1009A and VUIIS1009B share a common binding pocket within mammalian TSPO (mTSPO) as DPA-714 and to a lesser extent, PK11195. [18F]VUIIS1009A ([18F]3A) and [18F]VUIIS1009B ([18F]3B) exhibited similar biodistribution in healthy mice. In rats bearing C6 gliomas, both [18F]VUIIS1009A and [18F]VUIIS1009B exhibited greater binding potential (k 3/k 4)in tumor tissue compared to [18F]DPA-714. Interestingly, [18F]VUIIS1009B exhibited significantly greater tumor uptake (V T) than [18F]VUIIS1009A, which was attributed primarily to greater plasma-to-tumor extraction efficiency. CONCLUSIONS The novel PET ligand [18F]VUIIS1009B exhibits promising characteristics for imaging glioma; its superiority over [18F]VUIIS1009A, a regioisomer, appears to be primarily due to improved plasma extraction efficiency. Continued evaluation of [18F]VUIIS1009B as a high-affinity TSPO PET ligand for precision medicine appears warranted.
Collapse
Affiliation(s)
- Dewei Tang
- Vanderbilt University Institute of Imaging Science (VUIIS), Vanderbilt University Medical Center, Nashville, TN, 37232, USA.,Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, TN, 37232, USA.,Department of Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, China.,Shanghai Key Laboratory for Molecular Imaging, Shanghai University of Medicine and Health Sciences, Shanghai, 201318, China
| | - Jun Li
- Vanderbilt University Institute of Imaging Science (VUIIS), Vanderbilt University Medical Center, Nashville, TN, 37232, USA.,Interdisciplinary Materials Science Program, Department of Physics and Astronomy, Vanderbilt University, Nashville, TN, 37240, USA
| | - Jason R Buck
- Vanderbilt University Institute of Imaging Science (VUIIS), Vanderbilt University Medical Center, Nashville, TN, 37232, USA
| | - Mohamed Noor Tantawy
- Vanderbilt University Institute of Imaging Science (VUIIS), Vanderbilt University Medical Center, Nashville, TN, 37232, USA.,Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, TN, 37232, USA
| | - Yan Xia
- Center for Structural Biology (CSB), Vanderbilt University, Nashville, TN, 37205, USA.,Department of Chemistry, Vanderbilt University, Nashville, TN, 37235, USA
| | - Joel M Harp
- Department of Biochemistry, Vanderbilt University Medical Center, Nashville, TN, 37232, USA.,Department of Biological Sciences, Vanderbilt University, Nashville, TN, 37235, USA
| | - Michael L Nickels
- Vanderbilt University Institute of Imaging Science (VUIIS), Vanderbilt University Medical Center, Nashville, TN, 37232, USA.,Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, TN, 37232, USA
| | - Jens Meiler
- Center for Structural Biology (CSB), Vanderbilt University, Nashville, TN, 37205, USA.,Department of Chemistry, Vanderbilt University, Nashville, TN, 37235, USA.,Vanderbilt Institute of Chemical Biology (VICB), Vanderbilt University Medical Center, Nashville, TN, 37232, USA
| | - H Charles Manning
- Vanderbilt University Institute of Imaging Science (VUIIS), Vanderbilt University Medical Center, Nashville, TN, 37232, USA. .,Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, TN, 37232, USA. .,Department of Chemistry, Vanderbilt University, Nashville, TN, 37235, USA. .,Program in Chemical and Physical Biology, Vanderbilt University Medical Center, Nashville, TN, 37232, USA. .,Vanderbilt-Ingram Cancer Center (VICC), Vanderbilt University Medical Center, Nashville, TN, 37232, USA. .,Department of Biomedical Engineering, Vanderbilt University, Nashville, TN, 37232, USA. .,Department of Neurosurgery, Vanderbilt University Medical Center, Nashville, TN, 37232, USA.
| |
Collapse
|
15
|
Schulte ML, Fu A, Zhao P, Li J, Geng L, Smith ST, Kondo J, Coffey RJ, Johnson MO, Rathmell JC, Sharick JT, Skala MC, Smith JA, Berlin J, Washington MK, Nickels ML, Manning HC. Pharmacological blockade of ASCT2-dependent glutamine transport leads to antitumor efficacy in preclinical models. Nat Med 2018; 24:194-202. [PMID: 29334372 PMCID: PMC5803339 DOI: 10.1038/nm.4464] [Citation(s) in RCA: 272] [Impact Index Per Article: 45.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2017] [Accepted: 11/29/2017] [Indexed: 12/11/2022]
Abstract
The unique metabolic demands of cancer cells underscore potentially fruitful opportunities for drug discovery in the era of precision medicine. However, therapeutic targeting of cancer metabolism has led to surprisingly few new drugs to date. The neutral amino acid glutamine serves as a key intermediate in numerous metabolic processes leveraged by cancer cells, including biosynthesis, cell signaling, and oxidative protection. Herein we report the preclinical development of V-9302, a competitive small molecule antagonist of transmembrane glutamine flux that selectively and potently targets the amino acid transporter ASCT2. Pharmacological blockade of ASCT2 with V-9302 resulted in attenuated cancer cell growth and proliferation, increased cell death, and increased oxidative stress, which collectively contributed to antitumor responses in vitro and in vivo. This is the first study, to our knowledge, to demonstrate the utility of a pharmacological inhibitor of glutamine transport in oncology, representing a new class of targeted therapy and laying a framework for paradigm-shifting therapies targeting cancer cell metabolism.
Collapse
Affiliation(s)
- Michael L. Schulte
- Vanderbilt Center for Molecular Probes, Vanderbilt University Medical Center, Nashville, TN 37232, United States
- Vanderbilt University Institute of Imaging Science, Vanderbilt University Medical Center, Nashville, TN 37232, United States
- Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, TN 37232, United States
| | - Allie Fu
- Vanderbilt Center for Molecular Probes, Vanderbilt University Medical Center, Nashville, TN 37232, United States
| | - Ping Zhao
- Vanderbilt Center for Molecular Probes, Vanderbilt University Medical Center, Nashville, TN 37232, United States
| | - Jun Li
- Vanderbilt Center for Molecular Probes, Vanderbilt University Medical Center, Nashville, TN 37232, United States
| | - Ling Geng
- Vanderbilt Center for Molecular Probes, Vanderbilt University Medical Center, Nashville, TN 37232, United States
| | - Shannon T. Smith
- Vanderbilt Center for Molecular Probes, Vanderbilt University Medical Center, Nashville, TN 37232, United States
| | - Jumpei Kondo
- Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, United States
| | - Robert J. Coffey
- Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, United States
- Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN 37232, United States
- Veterans Health Administration, Tennessee Valley Healthcare System, Nashville, TN, 37212, United States
| | - Marc O. Johnson
- Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, United States
| | - Jeffrey C. Rathmell
- Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, United States
| | - Joe T. Sharick
- Department of Biomedical Engineering, Vanderbilt University, Nashville, TN 37232, United States
| | - Melissa C. Skala
- Department of Biomedical Engineering, Vanderbilt University, Nashville, TN 37232, United States
| | - Jarrod A. Smith
- Vanderbilt Center for Structural Biology, Vanderbilt University, Nashville, TN 37232, United States
- Department of Biochemistry, Vanderbilt University, Nashville, TN 37232, United States
| | - Jordan Berlin
- Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN 37232, United States
| | - M. Kay Washington
- Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN 37232, United States
- Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, United States
| | - Michael L. Nickels
- Vanderbilt Center for Molecular Probes, Vanderbilt University Medical Center, Nashville, TN 37232, United States
- Vanderbilt University Institute of Imaging Science, Vanderbilt University Medical Center, Nashville, TN 37232, United States
- Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, TN 37232, United States
| | - H. Charles Manning
- Vanderbilt Center for Molecular Probes, Vanderbilt University Medical Center, Nashville, TN 37232, United States
- Vanderbilt University Institute of Imaging Science, Vanderbilt University Medical Center, Nashville, TN 37232, United States
- Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, TN 37232, United States
- Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN 37232, United States
- Department of Biomedical Engineering, Vanderbilt University, Nashville, TN 37232, United States
- Department of Neurosurgery, Vanderbilt University Medical Center, Nashville, TN 37232, United States
- Department of Chemistry, Vanderbilt University, Nashville, TN 37232, United States
| |
Collapse
|
16
|
Li J, Smith JA, Dawson ES, Fu A, Nickels ML, Schulte ML, Manning HC. Optimized Translocator Protein Ligand for Optical Molecular Imaging and Screening. Bioconjug Chem 2017; 28:1016-1023. [PMID: 28156095 DOI: 10.1021/acs.bioconjchem.6b00711] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Translocator protein (TSPO) is a validated target for molecular imaging of a variety of human diseases and disorders. Given its involvement in cholesterol metabolism, TSPO expression is commonly elevated in solid tumors, including glioma, colorectal cancer, and breast cancer. TSPO ligands capable of detection by optical imaging are useful molecular tracers for a variety of purposes that range from quantitative biology to drug discovery. Leveraging our prior optimization of the pyrazolopyrimidine TSPO ligand scaffold for cancer imaging, we report herein a new generation of TSPO tracers with superior binding affinity and suitability for optical imaging and screening. In total, seven candidate TSPO tracers were synthesized and vetted in this study; the most promising tracer identified (29, Kd = 0.19 nM) was the result of conjugating a high-affinity TSPO ligand to a fluorophore used routinely in biological sciences (FITC) via a functional carbon linker of optimal length. Computational modeling suggested that an n-alkyl linker of eight carbons in length allows for positioning of the bulky fluorophore distal to the ligand binding domain and toward the solvent interface, minimizing potential ligand-protein interference. Probe 29 was found to be highly suitable for in vitro imaging of live TSPO-expressing cells and could be deployed as a ligand screening and discovery tool. Competitive inhibition of probe 29 quantified by fluorescence and 3H-PK11195 quantified by traditional radiometric detection resulted in equivalent affinity data for two previously reported TSPO ligands. This study introduces the utility of TSPO ligand 29 for in vitro imaging and screening and provides a structural basis for the development of future TSPO imaging ligands bearing bulky signaling moieties.
Collapse
Affiliation(s)
- Jun Li
- Interdisciplinary Materials Science Program, ∥Vanderbilt University Center for Structural Biology, and ■Department of Biomedical Engineering, Vanderbilt University , Nashville, Tennessee 37232, United States.,Vanderbilt University Institute of Imaging Science (VUIIS), §Center for Molecular Probes, ⊥Department of Radiology and Radiological Sciences, #Department of Biochemistry, ¶Vanderbilt-Ingram Cancer Center (VICC), and ▽Department of Neurosurgery, Vanderbilt University Medical Center , Nashville, Tennessee 37232, United States
| | - Jarrod A Smith
- Interdisciplinary Materials Science Program, ∥Vanderbilt University Center for Structural Biology, and ■Department of Biomedical Engineering, Vanderbilt University , Nashville, Tennessee 37232, United States.,Vanderbilt University Institute of Imaging Science (VUIIS), §Center for Molecular Probes, ⊥Department of Radiology and Radiological Sciences, #Department of Biochemistry, ¶Vanderbilt-Ingram Cancer Center (VICC), and ▽Department of Neurosurgery, Vanderbilt University Medical Center , Nashville, Tennessee 37232, United States
| | - Eric S Dawson
- Interdisciplinary Materials Science Program, ∥Vanderbilt University Center for Structural Biology, and ■Department of Biomedical Engineering, Vanderbilt University , Nashville, Tennessee 37232, United States.,Vanderbilt University Institute of Imaging Science (VUIIS), §Center for Molecular Probes, ⊥Department of Radiology and Radiological Sciences, #Department of Biochemistry, ¶Vanderbilt-Ingram Cancer Center (VICC), and ▽Department of Neurosurgery, Vanderbilt University Medical Center , Nashville, Tennessee 37232, United States
| | - Allie Fu
- Interdisciplinary Materials Science Program, ∥Vanderbilt University Center for Structural Biology, and ■Department of Biomedical Engineering, Vanderbilt University , Nashville, Tennessee 37232, United States.,Vanderbilt University Institute of Imaging Science (VUIIS), §Center for Molecular Probes, ⊥Department of Radiology and Radiological Sciences, #Department of Biochemistry, ¶Vanderbilt-Ingram Cancer Center (VICC), and ▽Department of Neurosurgery, Vanderbilt University Medical Center , Nashville, Tennessee 37232, United States
| | - Michael L Nickels
- Interdisciplinary Materials Science Program, ∥Vanderbilt University Center for Structural Biology, and ■Department of Biomedical Engineering, Vanderbilt University , Nashville, Tennessee 37232, United States.,Vanderbilt University Institute of Imaging Science (VUIIS), §Center for Molecular Probes, ⊥Department of Radiology and Radiological Sciences, #Department of Biochemistry, ¶Vanderbilt-Ingram Cancer Center (VICC), and ▽Department of Neurosurgery, Vanderbilt University Medical Center , Nashville, Tennessee 37232, United States
| | - Michael L Schulte
- Interdisciplinary Materials Science Program, ∥Vanderbilt University Center for Structural Biology, and ■Department of Biomedical Engineering, Vanderbilt University , Nashville, Tennessee 37232, United States.,Vanderbilt University Institute of Imaging Science (VUIIS), §Center for Molecular Probes, ⊥Department of Radiology and Radiological Sciences, #Department of Biochemistry, ¶Vanderbilt-Ingram Cancer Center (VICC), and ▽Department of Neurosurgery, Vanderbilt University Medical Center , Nashville, Tennessee 37232, United States
| | - H Charles Manning
- Interdisciplinary Materials Science Program, ∥Vanderbilt University Center for Structural Biology, and ■Department of Biomedical Engineering, Vanderbilt University , Nashville, Tennessee 37232, United States.,Vanderbilt University Institute of Imaging Science (VUIIS), §Center for Molecular Probes, ⊥Department of Radiology and Radiological Sciences, #Department of Biochemistry, ¶Vanderbilt-Ingram Cancer Center (VICC), and ▽Department of Neurosurgery, Vanderbilt University Medical Center , Nashville, Tennessee 37232, United States
| |
Collapse
|
17
|
Hassanein M, Hight MR, Buck JR, Tantawy MN, Nickels ML, Hoeksema MD, Harris BK, Boyd K, Massion PP, Manning HC. Preclinical Evaluation of 4-[18F]Fluoroglutamine PET to Assess ASCT2 Expression in Lung Cancer. Mol Imaging Biol 2016; 18:18-23. [PMID: 25971659 DOI: 10.1007/s11307-015-0862-4] [Citation(s) in RCA: 35] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
PURPOSE Alanine-serine-cysteine transporter 2 (ASCT2) expression has been demonstrated as a promising lung cancer biomarker. (2S,4R)-4-[(18)F]Fluoroglutamine (4-[(18)F]fluoro-Gln) positron emission tomography (PET) was evaluated in preclinical models of non-small cell lung cancer as a quantitative, non-invasive measure of ASCT2 expression. PROCEDURES In vivo microPET studies of 4-[(18)F]fluoro-Gln uptake were undertaken in human cell line xenograft tumor-bearing mice of varying ASCT2 levels, followed by a genetically engineered mouse model of epidermal growth factor receptor (EGFR)-mutant lung cancer. The relationship between a tracer accumulation and ASCT2 levels in tumors was evaluated by IHC and immunoblotting. RESULT 4-[(18)F]Fluoro-Gln uptake, but not 2-deoxy-2-[(18)F]fluoro-D-glucose, correlated with relative ASCT2 levels in xenograft tumors. In genetically engineered mice, 4-[(18)F]fluoro-Gln accumulation was significantly elevated in lung tumors, relative to normal lung and cardiac tissues. CONCLUSIONS 4-[(18)F]Fluoro-Gln PET appears to provide a non-invasive measure of ASCT2 expression. Given the potential of ASCT2 as a lung cancer biomarker, this and other tracers reflecting ASCT2 levels could emerge as precision imaging diagnostics in this setting.
Collapse
Affiliation(s)
- Mohamed Hassanein
- Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University School of Medicine, Nashville, TN, 37232, USA.,Thoracic Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, 37232, USA
| | - Matthew R Hight
- Vanderbilt University Institute of Imaging Science (VUIIS), Vanderbilt University Medical Center, Nashville, TN, 37232, USA.,Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, TN, 37232, USA
| | - Jason R Buck
- Vanderbilt University Institute of Imaging Science (VUIIS), Vanderbilt University Medical Center, Nashville, TN, 37232, USA.,Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, TN, 37232, USA
| | - Mohammed N Tantawy
- Vanderbilt University Institute of Imaging Science (VUIIS), Vanderbilt University Medical Center, Nashville, TN, 37232, USA.,Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, TN, 37232, USA
| | - Michael L Nickels
- Vanderbilt University Institute of Imaging Science (VUIIS), Vanderbilt University Medical Center, Nashville, TN, 37232, USA.,Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, TN, 37232, USA
| | - Megan D Hoeksema
- Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University School of Medicine, Nashville, TN, 37232, USA
| | - Bradford K Harris
- Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University School of Medicine, Nashville, TN, 37232, USA
| | - Kelli Boyd
- Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, 37232, USA
| | - Pierre P Massion
- Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University School of Medicine, Nashville, TN, 37232, USA.,Thoracic Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, 37232, USA.,Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, 37232, USA
| | - H Charles Manning
- Vanderbilt University Institute of Imaging Science (VUIIS), Vanderbilt University Medical Center, Nashville, TN, 37232, USA. .,Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, TN, 37232, USA. .,Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, 37232, USA. .,Program in Chemical and Physical Biology, Vanderbilt University Medical Center, Nashville, TN, 37232, USA.
| |
Collapse
|
18
|
Li J, Schulte ML, Nickels ML, Manning HC. New structure-activity relationships of N-acetamide substituted pyrazolopyrimidines as pharmacological ligands of TSPO. Bioorg Med Chem Lett 2016; 26:3472-7. [PMID: 27353534 DOI: 10.1016/j.bmcl.2016.06.041] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2016] [Revised: 06/13/2016] [Accepted: 06/15/2016] [Indexed: 11/26/2022]
Abstract
Translocator protein (TSPO) represents an attractive target for molecular imaging and therapy due to its prevalence and critical roles played in oncology and other pathologies. Based upon our previously optimized pyrazolopyrimidine scaffold, we elucidated new structure activity relationships related to N,N-disubstitutions of the terminal acetamide on pyrazolopyrimidines and further explored the impacts of these substituents on lipophilicity and plasma protein binding. Several novel chemical probes reported here exhibited significantly increased binding affinity, suitable lipophilicity and protein binding compared with contemporary TSPO ligands. We illustrate that N,N-acetamide disubstitution affords opportunities to introduce diverse chemical moieties distal to the central pyrazolopyrimidine core, without sacrificing TSPO affinity. We anticipate that further exploration of N-acetamide substitutions may yield additional TSPO ligands capable of furthering the field of precision medicine.
Collapse
Affiliation(s)
- Jun Li
- Interdisciplinary Materials Science Program, Vanderbilt University, Nashville, TN 37232, United States; Vanderbilt University Institute of Imaging Science (VUIIS), Vanderbilt University Medical Center, Nashville, TN 37232, United States; Center for Molecular Probes, Vanderbilt University Medical Center, Nashville, TN 37232, United States
| | - Michael L Schulte
- Vanderbilt University Institute of Imaging Science (VUIIS), Vanderbilt University Medical Center, Nashville, TN 37232, United States; Center for Molecular Probes, Vanderbilt University Medical Center, Nashville, TN 37232, United States; Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, TN 37232, United States
| | - Michael L Nickels
- Vanderbilt University Institute of Imaging Science (VUIIS), Vanderbilt University Medical Center, Nashville, TN 37232, United States; Center for Molecular Probes, Vanderbilt University Medical Center, Nashville, TN 37232, United States; Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, TN 37232, United States
| | - H Charles Manning
- Interdisciplinary Materials Science Program, Vanderbilt University, Nashville, TN 37232, United States; Vanderbilt University Institute of Imaging Science (VUIIS), Vanderbilt University Medical Center, Nashville, TN 37232, United States; Center for Molecular Probes, Vanderbilt University Medical Center, Nashville, TN 37232, United States; Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, TN 37232, United States; Program in Chemical and Physical Biology, Vanderbilt University Medical Center, Nashville, TN 37232, United States; Vanderbilt-Ingram Cancer Center (VICC), Vanderbilt University Medical Center, Nashville, TN 37232, United States; Department of Biomedical Engineering, Vanderbilt University, Nashville, TN 37232, United States; Department of Chemistry, Vanderbilt University, Nashville, TN 37232, United States; Department of Neurosurgery, Vanderbilt University Medical Center, Nashville, TN 37232, United States.
| |
Collapse
|
19
|
Tang D, Nickels ML, Tantawy MN, Buck JR, Manning HC. Preclinical imaging evaluation of novel TSPO-PET ligand 2-(5,7-Diethyl-2-(4-(2-[(18)F]fluoroethoxy)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)-N,N-diethylacetamide ([ (18)F]VUIIS1008) in glioma. Mol Imaging Biol 2015; 16:813-20. [PMID: 24845529 DOI: 10.1007/s11307-014-0743-2] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
PURPOSE Translocator protein (TSPO) concentrations are elevated in glioma, suggesting a role for TSPO positron emission tomography (PET) imaging in this setting. In preclinical PET studies, we evaluated a novel, high-affinity TSPO PET ligand, [(18)F]VUIIS1008, in healthy mice and glioma-bearing rats. PROCEDURES Dynamic PET data were acquired simultaneously with [(18)F]VUIIS1008 injection, with binding reversibility and specificity evaluated in vivo by non-radioactive ligand displacement or blocking. Compartmental analysis of PET data was performed using metabolite-corrected arterial input functions. Imaging was validated with histology and immunohistochemistry. RESULTS [(18)F]VUIIS1008 exhibited rapid uptake in TSPO-rich organs. PET ligand uptake was displaceable with non-radioactive VUIIS1008 or PBR06 in mice. Tumor accumulation of [(18)F]VUIIS1008 was blocked by pretreatment with VUIIS1008 in rats. [(18)F]VUIIS1008 exhibited improved tumor-to-background ratio and higher binding potential in tumors compared to a structurally similar pyrazolopyrimidine TSPO ligand, [(18)F]DPA-714. CONCLUSIONS The PET ligand [(18)F]VUIIS1008 exhibits promising characteristics as a tracer for imaging glioma. Further translational studies appear warranted.
Collapse
Affiliation(s)
- Dewei Tang
- Vanderbilt University Institute of Imaging Science (VUIIS), Vanderbilt University Medical Center, 1161 21st Ave. S., AA 1105 MCN, Nashville, TN, 37232-2310, USA
| | | | | | | | | |
Collapse
|
20
|
Cheung YY, Buck JR, Nickels ML, Tang D, Manning HC. Abstract 110: Preclinical evaluation of 7-chloro-N,N,5-trimethyl-4-oxo-3(6-[18F]fluoropyridin-2-yl)-3,5-dihydro-4H-pyridazino[4,5-b]indole-1-acetamide: A novel pyridazinoindole ligand for PET imaging of TSPO in cancer. Cancer Res 2014. [DOI: 10.1158/1538-7445.am2014-110] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
There exists a continued need for the development of improved positron emission tomography (PET) biomarkers for glioma imaging to aid in tumor diagnosis, inform clinical outcome, and quantify response to therapeutic intervention. Translocator protein (TSPO) expression is elevated in cancer and has been linked with disease progression and diminished survival and tends to be a hallmark of aggressive tumors. Our laboratory has pursued development of TSPO PET ligands as candidates for molecular imaging of glioma, as TSPO ligand binding correlates with tumor grade in this setting.
We report the first exploration of the structure-activity relationship (SAR) around the pyridazinoindole ring and subsequent radiofluorination of a potent and novel pyridazinoindole-based TSPO-selective ligand for cancer imaging. Library and SAR development around the N3 position of the pyridazinoindole scaffold led to the discovery of 7-chloro-N,N,5-trimethyl-4-oxo-3(6-fluoropyridin-2-yl)-3,5-dihydro-4H-pyridazino[4,5-b]indole-1-acetamide (VUIIS8310), a novel TSPO ligand exhibiting a binding affinity comparable to SSR180575, yet bearing a fluorine atom for subsequent radiolabeling with fluorine-18 (18F) to give 7-chloro-N,N,5-trimethyl-4-oxo-3(6-[18F]fluoropyridin-2-yl)-3,5-dihydro-4H-pyridazino[4,5-b]indole-1-acetamide (18F-VUIIS8310).
Initial production feasibility and radiochemical development were evaluated with microfluidics and subsequently translated to traditional box-based methods. Subsequently, quantitative, preclinical elevation of 18F-VUIIS8310 was conducted in a rat glioma model, given our previous experience in this setting. Glioma-bearing rats were imaged in a microPET system, with dynamic PET acquisitions acquired simultaneously upon tracer injection. PET ligand reversibility and specificity were evaluated by ligand displacement studies that utilized VUIIS8310. 18F-VUIIS8310 exhibited elevated uptake and specific, displaceable binding in tumor, in contrast with normal brain, which exhibited very low uptake. 18F-VUIIS8310 uptake in the tumor, relative to normal brain, reached a tumor-to-normal brain ratio of greater than 10:1. Ex vivo histological analysis of resected tissue correlated well with PET imaging data.
These preclinical studies illuminate 18F-VUIIS8310 as a promising, novel TSPO PET ligand for imaging glioma and potentially other solid tumors. Importantly, the in vivo stability and high signal-to-noise achieved between tumor and surrounding normal brain suggest the potential of this PET ligand for early tumor detection within this setting. Future head-to-head comparisons between this tracer and emerging, potent TSPO ligands (J. Med. Chem. 2013, 56, 3429) are underway.
Citation Format: Yiu-Yin Cheung, Jason R. Buck, Michael L. Nickels, Dewei Tang, H. Charles Manning. Preclinical evaluation of 7-chloro-N,N,5-trimethyl-4-oxo-3(6-[18F]fluoropyridin-2-yl)-3,5-dihydro-4H-pyridazino[4,5-b]indole-1-acetamide: A novel pyridazinoindole ligand for PET imaging of TSPO in cancer. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 110. doi:10.1158/1538-7445.AM2014-110
Collapse
Affiliation(s)
- Yiu-Yin Cheung
- 1Vanderbilt University Institute of Imaging Science, Nashville, TN
| | - Jason R. Buck
- 1Vanderbilt University Institute of Imaging Science, Nashville, TN
| | | | - Dewei Tang
- 1Vanderbilt University Institute of Imaging Science, Nashville, TN
| | | |
Collapse
|
21
|
Cheung YY, Nickels ML, Tang D, Buck JR, Manning HC. Facile synthesis of SSR180575 and discovery of 7-chloro-N,N,5-trimethyl-4-oxo-3(6-[(18)F]fluoropyridin-2-yl)-3,5-dihydro-4H-pyridazino[4,5-b]indole-1-acetamide, a potent pyridazinoindole ligand for PET imaging of TSPO in cancer. Bioorg Med Chem Lett 2014; 24:4466-4471. [PMID: 25172419 PMCID: PMC4163096 DOI: 10.1016/j.bmcl.2014.07.091] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2014] [Revised: 07/29/2014] [Accepted: 07/31/2014] [Indexed: 10/24/2022]
Abstract
A novel synthesis of the translocator protein (TSPO) ligand 7-chloro-N,N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4H-pyridazino[4,5-b]indole-1-acetamide (SSR180575, 3) was achieved in four steps from commercially available starting materials. Focused structure-activity relationship development about the pyridazinoindole ring at the N3 position led to the discovery of 7-chloro-N,N,5-trimethyl-4-oxo-3(6-fluoropyridin-2-yl)-3,5-dihydro-4H-pyridazino[4,5-b]indole-1-acetamide (14), a novel ligand of comparable affinity. Radiolabeling with fluorine-18 ((18)F) yielded 7-chloro-N,N,5-trimethyl-4-oxo-3(6-[(18)F]fluoropyridin-2-yl)-3,5-dihydro-4H-pyridazino[4,5-b]indole-1-acetamide ([(18)F]-14) in high radiochemical yield and specific activity. In vivo studies of [(18)F]-14 revealed this agent as a promising probe for molecular imaging of glioma.
Collapse
Affiliation(s)
- Yiu-Yin Cheung
- Vanderbilt University Institute of Imaging Science (VUIIS), Vanderbilt University Medical Center, Nashville, TN 37232, United States
| | - Michael L Nickels
- Vanderbilt University Institute of Imaging Science (VUIIS), Vanderbilt University Medical Center, Nashville, TN 37232, United States; Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, TN 37232, United States
| | - Dewei Tang
- Vanderbilt University Institute of Imaging Science (VUIIS), Vanderbilt University Medical Center, Nashville, TN 37232, United States; Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, TN 37232, United States
| | - Jason R Buck
- Vanderbilt University Institute of Imaging Science (VUIIS), Vanderbilt University Medical Center, Nashville, TN 37232, United States; Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, TN 37232, United States
| | - H Charles Manning
- Vanderbilt University Institute of Imaging Science (VUIIS), Vanderbilt University Medical Center, Nashville, TN 37232, United States; Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, TN 37232, United States; Program in Chemical and Physical Biology, Vanderbilt University Medical Center, Nashville, TN 37232, United States; Vanderbilt-Ingram Cancer Center (VICC), Vanderbilt University Medical Center, Nashville, TN 37232, United States; Department of Biomedical Engineering, Vanderbilt University, Nashville, TN 37232, United States; Department of Neurosurgery, Vanderbilt University Medical Center, Nashville, TN 37232, United States
| |
Collapse
|
22
|
Hight MR, Cheung YY, Nickels ML, Dawson ES, Zhao P, Saleh S, Buck JR, Tang D, Washington MK, Coffey RJ, Manning HC. A peptide-based positron emission tomography probe for in vivo detection of caspase activity in apoptotic cells. Clin Cancer Res 2014; 20:2126-35. [PMID: 24573549 DOI: 10.1158/1078-0432.ccr-13-2444] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
PURPOSE Apoptosis, or programmed cell death, can be leveraged as a surrogate measure of response to therapeutic interventions in medicine. Cysteine aspartic acid-specific proteases, or caspases, are essential determinants of apoptosis signaling cascades and represent promising targets for molecular imaging. Here, we report development and in vivo validation of [(18)F]4-fluorobenzylcarbonyl-Val-Ala-Asp(OMe)-fluoromethylketone ([(18)F]FB-VAD-FMK), a novel peptide-based molecular probe suitable for quantification of caspase activity in vivo using positron emission tomography (PET). EXPERIMENTAL DESIGN Supported by molecular modeling studies and subsequent in vitro assays suggesting probe feasibility, the labeled pan-caspase inhibitory peptide, [(18)F]FB-VAD-FMK, was produced in high radiochemical yield and purity using a simple two-step, radiofluorination. The biodistribution of [(18)F]FB-VAD-FMK in normal tissue and its efficacy to predict response to molecularly targeted therapy in tumors was evaluated using microPET imaging of mouse models of human colorectal cancer. RESULTS Accumulation of [(18)F]FB-VAD-FMK was found to agree with elevated caspase-3 activity in response to Aurora B kinase inhibition as well as a multidrug regimen that combined an inhibitor of mutant BRAF and a dual PI3K/mTOR inhibitor in (V600E)BRAF colon cancer. In the latter setting, [(18)F]FB-VAD-FMK PET was also elevated in the tumors of cohorts that exhibited reduction in size. CONCLUSIONS These studies illuminate [(18)F]FB-VAD-FMK as a promising PET imaging probe to detect apoptosis in tumors and as a novel, potentially translatable biomarker for predicting response to personalized medicine.
Collapse
Affiliation(s)
- Matthew R Hight
- Authors' Affiliations: Interdisciplinary Materials Science Program, Department of Physics & Astronomy, Departments of Biochemistry, Pathology, Cell and Developmental Biology, and Biomedical Engineering; Vanderbilt University Center for Structural Biology (CSB), Vanderbilt University; Vanderbilt University Institute of Imaging Science (VUIIS); Departments of Radiology and Radiological Sciences and Neurosurgery; Vanderbilt-Ingram Cancer Center (VICC); Program in Chemical and Physical Biology, Vanderbilt University Medical Center; Department of Medicine, Vanderbilt University Medical School; and Department of Veterans Affairs Medical Center, Nashville, Tennessee
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Tang D, McKinley ET, Hight MR, Uddin MI, Harp JM, Fu A, Nickels ML, Buck JR, Manning HC. Synthesis and structure-activity relationships of 5,6,7-substituted pyrazolopyrimidines: discovery of a novel TSPO PET ligand for cancer imaging. J Med Chem 2013; 56:3429-33. [PMID: 23521048 DOI: 10.1021/jm4001874] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Focused library synthesis and structure-activity relationship development of 5,6,7-substituted pyrazolopyrimidines led to the discovery of 2-(5,7-diethyl-2-(4-(2-fluoroethoxy)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)-N,N-diethylacetamide (6b), a novel translocator protein (TSPO) ligand exhibiting a 36-fold enhancement in affinity compared to another pyrazolopyrimidine-based TSPO ligand, 6a (DPA-714). Radiolabeling with fluorine-18 ((18)F) facilitated production of 2-(5,7-diethyl-2-(4-(2-[(18)F]fluoroethoxy)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)-N,N-diethylacetamide ((18)F-6b) in high radiochemical yield and specific activity. In vivo studies of (18)F-6b were performed which illuminated this agent as an improved probe for molecular imaging of TSPO-expressing cancers.
Collapse
Affiliation(s)
- Dewei Tang
- Vanderbilt University Institute of Imaging Science (VUIIS), Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Nolting DD, Nickels ML, Guo N, Pham W. Molecular imaging probe development: a chemistry perspective. Am J Nucl Med Mol Imaging 2012; 2:273-306. [PMID: 22943038 PMCID: PMC3430472] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Subscribe] [Scholar Register] [Received: 06/01/2012] [Accepted: 06/29/2012] [Indexed: 06/01/2023]
Abstract
Molecular imaging is an attractive modality that has been widely employed in many aspects of biomedical research; especially those aimed at the early detection of diseases such as cancer, inflammation and neurodegenerative disorders. The field emerged in response to a new research paradigm in healthcare that seeks to integrate detection capabilities for the prediction and prevention of diseases. This approach made a distinct impact in biomedical research as it enabled researchers to leverage the capabilities of molecular imaging probes to visualize a targeted molecular event non-invasively, repeatedly and continuously in a living system. In addition, since such probes are inherently compact, robust, and amenable to high-throughput production, these probes could potentially facilitate screening of preclinical drug discovery, therapeutic assessment and validation of disease biomarkers. They could also be useful in drug discovery and safety evaluations. In this review, major trends in the chemical synthesis and development of positron emission tomography (PET), optical and magnetic resonance imaging (MRI) probes are discussed.
Collapse
Affiliation(s)
- Donald D Nolting
- Vanderbilt University Institute of Imaging ScienceNashville, TN, USA
| | - Michael L Nickels
- Vanderbilt University Institute of Imaging ScienceNashville, TN, USA
| | - Ning Guo
- Vanderbilt University Institute of Imaging ScienceNashville, TN, USA
| | - Wellington Pham
- Vanderbilt University Institute of Imaging ScienceNashville, TN, USA
- Department of Biomedical Engineering, Vanderbilt UniversityNashville, TN, USA
- Vanderbilt Ingram Cancer CenterNashville, TN, USA
| |
Collapse
|